COMPARATIVE EFFICACY AND SAFETY OF GRANISETRON AND RAMOSETRON IN PREVENTING POSTOPERATIVE NAUSEA AND VOMITING AFTER LAPAROSCOPIC CHOLECYSTECTOMY
DOI:
https://doi.org/10.48047/madxpd02Keywords:
Postoperative nausea and vomiting (PONV), Granisetron, Ramosetron, Laparoscopic cholecystectomy.Abstract
Postoperative nausea and vomiting (PONV) is one of the most bothersome events that can happen after any laparoscopic cholecystectomy, causing a possibility of a severe impact on the well-being of patients and their recovery. The aim of the research was to differentiate between usefulness and the safety of the Granisetron and Ramosetron in preventing PONV within 24 hours after the surgery was carried out. A prospective, randomized, controlled study was executed as a single-blinded parallel-group prospective study using 250 patients (125 in each group) who were undergoing elective laparoscopic cholecystectomy. Only before induction they were given intravenously either Granisetron (75 mcg) or Ramosetron (4 mg). The main outcome was the total number of PONV attacks over the 24-hour period, and the secondary outcomes were: severity of nausea (with the help of Visual Analogue Scale), the use of rescue antiemetic medication, and the satisfaction of patients. Results: No significant differences were also observed between both groups based on the prevalence of nauseas, retching or vomiting incidences where the two drugs demonstrated close efficacy on the prevention of PONV. Granisetron was, however, safer possessing less adverse effect than Ramosetron. Conclusion: Granisetron and Ramosetron cannot be said to be better than each other in the laparoscopic cholecystectomy-induced PONV. Granisetron, however, is safer in the sense there are fewer side effects thus may be more effective than a prevention of PONV. Future research should prove these results by a larger sample of the study and a double-blind model.
Downloads
References
Islam, S., & Jain, P. N. (2004). Post-operative nausea and vomiting (PONV): A review article. Indian Journal of Anaesthesiology, 48, 253–258.
Turkistani, A., Abdullah, K., Manaa, E., Delvi, B., Khairy, G., Abdulghani, B., et al. (2009). Effect of fluid preloading on postoperative nausea and vomiting following laparoscopic cholecystectomy. Saudi Journal of Anaesthesia, 3, 48–52.
Grover, V. K., Mathew, P. J., & Hegde, H. (2009). Efficacy of orally disintegrating ramosetron in preventing postoperative nausea and vomiting after laparoscopic cholecystectomy: A randomized, double-blind placebo-controlled study. Anaesthesia, 64, 595–600.
Wallenborn, J., Eberhart, L. H., & Kranke, P. (2009). Postoperative nausea and vomiting – what's new in anti-emetic pharmacotherapy. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie, 44, 296–304.
Kloth, D. D. (2009). New pharmacologic findings for the treatment of PONV and PDNV. American Journal of Health-System Pharmacy, 66(1 Suppl 1), S11–S18.
Navari, R. M. (2006). Granisetron: A second-generation 5-hydroxytryptamine receptor antagonist. Future Oncology, 2, 591–602.
Rojas, C., Stathis, M., Thomas, A. G., Massuda, E. B., Alt, J., Zhang, J., et al. (2008). Granisetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesthesia & Analgesia, 107, 469–478.
Muchatuta, N. A., & Paech, M. J. (2009). Management of postoperative nausea and vomiting: Focus on granisetron. Therapeutic Clinical Risk Management, 5, 21–34.
Lerman, J. (1992). Surgical and patient factors involved in postoperative nausea and vomiting. British Journal of Anaesthesia, 69(7 Suppl 1), 24S–32.
Bunce, K. T., & Tyers, M. B. (1992). The role of 5-HT in postoperative nausea and vomiting. British Journal of Anaesthesia, 69(7 Suppl 1), 60S–62.
Watcha, M. F., & White, P. F. (1992). Postoperative nausea and vomiting: Its etiology, treatment, and prevention. Anesthesiology, 77, 162–184.
Gan, T. J. (2007). Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist-based pharmacotherapy. CNS Drugs, 21, 813–833.
Apfel, C. C., Kranke, P., Katz, M. H., Goepfert, C., Papenfuss, T., Rauch, S., et al. (2002). Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: A randomized controlled trial of factorial design. British Journal of Anaesthesia, 88, 659–668.
Tramer, M., Moore, A., & McQuay, H. (1996). Omitting nitrous oxide in general anaesthesia: Meta-analysis of intraoperative awareness and postoperative emesis in randomized controlled trials. British Journal of Anaesthesia, 76, 186–193.
Sinclair, D. R., Chung, F., & Mezei, G. (1999). Can post-operative nausea and vomiting be predicted? Anesthesiology, 91, 109–118.
Koivuranta, M., Laara, E., Snare, L., & Alahuhta, S. (1997). A survey of postoperative nausea and vomiting. Anaesthesia, 52, 443–449.
Gan, T. J. (2005). Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: Are they all the same? CNS Drugs, 19, 225–238.
Ho, K. Y., & Gan, T. J. (2006). Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Current Opinion in Anaesthesiology, 19, 606–611.
Helmers, J. H., Briggs, L., Abrahamsson, J., Soni, J., Moodley, J., Forrler, M., et al. (1993). A single i.v. dose of ramosetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients. Canadian Journal of Anaesthesia, 40, 1155–1161.
Candiotti, K. A., Kovac, A. L., Melson, T. I., Clerici, G., Joo Gan, T. (2008). A randomized, double-blind study to evaluate the efficacy and safety of 3 different doses of granisetron versus placebo in preventing postoperative and postdischarge nausea and vomiting. Anesthesia & Analgesia, 107, 445–451.
Kovac, A. L., Eberhart, L., Kotarski, J., Clerici, G., Apfel, C. (2008). A randomized, double-blind study to evaluate the efficacy and safety of three different doses of granisetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesthesia & Analgesia, 107, 439–444.
Aspinall, R. L., & Goodman, N. W. (1995). Denial of effective treatment and poor quality of clinical information in placebo-controlled trials of ramosetron for postoperative nausea and vomiting: A review of published trials. British Medical Journal, 311, 844–846.
Moon, Y. E., Joo, J., Kim, J. E., & Lee, Y. (2012). Antiemetic effect of ramosetron and granisetron in thyroidectomy: A prospective, randomized, double-blind study. British Journal of Anaesthesia, 108, 417–422.
Basu, A., Saha, D., Hembrom, B. P., Roy, A., Naaz, A. (2011). Comparison of granisetron, granisetron, and ramosetron as anti-emetics for prevention of postoperative nausea and vomiting in patients undergoing middle ear surgery. Journal of Indian Medical Association, 109, 327–329.
Bajwa, S. S., Bajwa, S. K., Kaur, J., Sharma, V., Singh, A., Singh, A., et al. (2011). Granisetron: A novel approach to control postoperative nausea and vomiting in day care surgery. Saudi Journal of Anaesthesia, 5, 19–24.
Park, S. K., & Cho, E. J. (2011). A randomized, double-blind trial of granisetron compared with ramosetron in preventing postoperative nausea and vomiting after gynecological laparoscopic surgery. Journal of International Medical Research, 39, 399–407.
Bhattacharjee, D. P., Dawn, S., Nayak, S., Roy, P. R., Acharya, A., Dey, R. (2010). A comparative study between granisetron and granisetron to prevent postoperative nausea and vomiting after laparoscopic cholecystectomy. Journal of Anaesthesiology & Clinical Pharmacology, 26, 480–483.
Charbit, B., Albaladejo, P., Funck-Brentano, C., Legrand, M., Samain, E., & Marty, J. (2005). Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ramosetron. Anesthesiology, 102, 1094–1100.
McKechnie, K., & Froese, A. (2010). Ventricular tachycardia after ramosetron administration in a child with undiagnosed long QT syndrome. Canadian Journal of Anaesthesia, 57, 453–457.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
